(IN BRIEF) Sanofi has received approval from Japan’s Ministry of Health, Labour and Welfare for the subcutaneous formulation of Sarclisa, or isatuximab, in combination with approved standard-of-care regimens for multiple myeloma. The approval covers use with pomalidomide and dexamethasone, or … Read the full press release →
Posted in European Union, France, Government, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anemia, anti-CD38 monoclonal antibody, anticancer treatment, bortezomib, cancer treatment, carfilzomib, CirCLIQ on-body injector, COVID-19, dexamethasone, Enable Injections, enFuse platform, European Union, hematologic malignancy, immunological therapies, infusion reactions, injection-site reactions, IRAKLIA phase 3 study, isatuximab, Japan, Japan Approval of Sarclisa Subcutaneous Builds on Phase 3 IRAKLIA Study Results, Japan Approves Sanofi’s Sarclisa Subcutaneous for Newly Diagnosed and Relapsed Multiple Myeloma, Japan Ministry of Health Labour and Welfare, Kd, lenalidomide, manual subcutaneous injection, Multiple Myeloma, NCT05405166, NDMM, neutropenia, newly diagnosed multiple myeloma, non-inferior efficacy, objective response rate, Olivier Nataf, on-body injector, oncology, ORR, Pd, pharmacokinetics, pneumonia, pomalidomide, R/R MM, relapsed or refractory multiple myeloma, Sanofi, Sanofi’s Sarclisa Subcutaneous Approval in Japan Expands Treatment Delivery Options for Multiple Myeloma Patients, Sarclisa, standard-of-care regimens, Subcutaneous formulation, targeted therapies, thrombocytopenia, United States, upper respiratory tract infection, VRd
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
